header logo image


Page 15«..10..14151617..2030..»

Archive for the ‘Genetics’ Category

The Wilderness of Rare Genetic Diseases and the Parents Navigating It – The New York Times

Wednesday, July 8th, 2020

A confirmed diagnosis may take time.

Diagnosis represents the first step on this rare disease journey. Sometimes doctors will notice something off about the child during a newborn screening, and a genetic test will identify a known mutation in the DNA. But not all conditions are so quickly detected, and it can take several years for parents to get a confirmed diagnosis.

About half of all children never get that far, according to Marshall Summar, M.D., the director of the Rare Disease Institute at Childrens National Hospital in Washington, D.C. When you sequence someones DNA, you are going to find a lot of changes, Dr. Summar said. Figuring out which change might be the one that is causing it is a tremendous challenge.

Genetic counselors warn parents beforehand that they may not get a definitive answer as to what condition their child could have. They may have to check back each year. Dr. Summar estimates that between five and 10 new rare diseases are described in the scientific literature every week, making it challenging for the medical field to keep up.

Meanwhile, the realization that a child may have a debilitating, lifelong condition weighs heavily. Some parents, particularly mothers, blame themselves, said Lemuel Pelentsov, Ph.D., a nurse who studies the needs of rare disease families at the University of South Australia, in Adelaide. In a 2016 study by Dr. Pelentsov and his colleagues, about 40 percent of the 300 rare parents surveyed reported being treated for depression and an equal number for anxiety. One of the things they do to combat that, he said, is get very invested in the childs disease.

When parents reach out to other parents, they are not simply looking for emotional support or advice. They are rebuilding a social life, one that will revolve around their childs disease. Many rare diseases have their own support groups. Global Genes is an umbrella group that supports 600 disease-specific foundations, as well as parents of children whose diseases are so rare they have no foundation.

We encourage folks to work together, said Kimberly Haugstad, the organizations executive director whose son has a rare form of hemophilia, a condition in which the blood doesnt clot normally. The parent is going to come from such different places in their own walk of life.

Each year, Global Genes hosts a Rare Boot Camp to mentor and teach parents how to set up a nonprofit, create patient registries and fund research. After attending the boot camp, the Van Wyks and other parents founded GACI Global, an organization that connects families affected by GACI, along with medical professionals.

Go here to see the original:
The Wilderness of Rare Genetic Diseases and the Parents Navigating It - The New York Times

Read More...

ACMG’s Genetics in Medicine Journal Receives Impact Factor of 8.904 for 2019–Journal is Ranked 13th of 177 Journals in Genetics & Heredity -…

Wednesday, July 8th, 2020

BETHESDA, Md., July 8, 2020 /PRNewswire/ --The American College of Medical Genetics and Genomics (ACMG) announced today that the 2019 Journal Impact Factors, published by Clarivate Analytics in the latest edition of Journal Citation Reports, calculated an impact factor of 8.904 for ACMG's official journal, Genetics in Medicine (GIM). This is the second highest Impact Factor in the journal's history and ranks GIM 13th of 177 titles in the Genetics & Heredity category.

The Impact Factor is an objective measure of the world's leading journals, based on articles' cited references and is oft considered a measure of a journal's impact, overall successful performance and relevance to its field. The most highly cited article in GIM in 2019 was "Recommendations for Reporting of Secondary Findings in Clinical Exome and Genome Sequencing, 2016 Update (ACMG SF v2.0): A Policy Statement of the American College of Medical Genetics and Genomics."

"GIM's editors and editorial staff are delighted that our Impact Factor has increased from last year. This improvement in the Impact Factor once again demonstrates that the journal remains one of the most widely read and cited journals publishing clinically relevant research in the life sciences," said GIM's Editor-in-Chief Robert D. Steiner, MD, FAAP, FACMG."We are most thankful to the peer reviewers who put in countless hours to help maintain the outstanding quality of articles and the authors who trust us to disseminate their groundbreaking scholarly work. The Impact Factor is one of a number of metrics used to evaluate journals, and a journal should not be evaluated solely on that one metric. Genetics in Medicine'scontinued success and relevance is also reflected in our very high overall downloads and reads as well as a prominent social media presence."

ACMG CEO Maximilian Muenke, MD, FACMG said, "As the CEO of the ACMG, I am extremely proud of 'our' journal. As a physician-scientist who before joining ACMG worked in academic settings where publishing in high-impact factor journals was the goal, I am well aware of the importance of this metric. My congratulations and gratitude on increasing GIM's impact factor go to Bob Steiner, Jan Higgins, the GIM staff and the entire editorial team to make this success happen!"

Genetics in Medicineis published by Springer Nature. The journal, published since 1998, is supported by an expert board of editors representing all facets of genetic and genomic medicine, including biochemical and molecular genetics, cytogenetics, and the application of genetics and genomics to other medical specialties such as oncology, cardiology, neurology, pediatrics, ophthalmology and maternal-fetal medicine.

About the American College of Medical Genetics and Genomics (ACMG) and ACMG Foundation

Founded in 1991, the American College of Medical Genetics and Genomics (ACMG) is the only nationally recognized medical professional organization solely dedicated to improving health through the practice of medical genetics and genomics, and the only medical specialty society in the US that represents the full spectrum of medical genetics disciplines in a single organization. The ACMG is the largest membership organization specifically for medical geneticists, providing education, resources and a voice for more than 2,300 clinical and laboratory geneticists, genetic counselors and other healthcare professionals, nearly 80% of whom are board certified in the medical genetics specialties. ACMG's mission is to improve health through the clinical and laboratory practice of medical genetics as well as through advocacy, education and clinical research, and to guide the safe and effective integration of genetics and genomics into all of medicine and healthcare, resulting in improved personal and public health. Four overarching strategies guide ACMG's work: 1) to reinforce and expand ACMG's position as the leader and prominent authority in the field of medical genetics and genomics, including clinical research, while educating the medical community on the significant role that genetics and genomics will continue to play in understanding, preventing, treating and curing disease; 2) to secure and expand the professional workforce for medical genetics and genomics; 3) to advocate for the specialty; and 4) to provide best-in-class education to members and nonmembers. Genetics in Medicine, published monthly, is the official ACMG journal. ACMG's website (www.acmg.net) offers resources including policy statements, practice guidelines, educational programs and a 'Find a Genetic Service' tool. The educational and public health programs of the ACMG are dependent upon charitable gifts from corporations, foundations and individuals through the ACMG Foundation for Genetic and Genomic Medicine.

Kathy Moran, MBA[emailprotected]

SOURCE American College of Medical Genetics and Genomics

http://www.acmg.net

Continue reading here:
ACMG's Genetics in Medicine Journal Receives Impact Factor of 8.904 for 2019--Journal is Ranked 13th of 177 Journals in Genetics & Heredity -...

Read More...

Global Hereditary Genetic Testing Market: Focus on Product, Sample, Technology, Genetic Testing Type, Application Area, Country Data (16 Countries),…

Wednesday, July 8th, 2020

New York, July 08, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Hereditary Genetic Testing Market: Focus on Product, Sample, Technology, Genetic Testing Type, Application Area, Country Data (16 Countries), and Competitive Landscape - Analysis and Forecast, 2020-2030" - https://www.reportlinker.com/p05930381/?utm_source=GNW

Product Type:Kits, Consumables, and Services Sample Type: Tumor Tissue, Blood, Saliva, Bone Marrow Technology: Next Generation Sequencing, Polymerase Chain Reaction,Immunohistochemistry, In-situ Hybridization, Microarray Techniques Oncology Genetic Testing: Breast, Colorectal,Prostate, Lung, Melanoma Cardiology Genetic Testing: Cardiomyopathy,Aortopathy, Arrythmia Neurology Genetic Testing: Epilepsy, Neurodegenerative Disorders, Neuromuscular Disorders Other Genetic Testing: Newborn Screening, NIPT, Rare Disease Testing, Direct to Consumer Testing Application Area: Academia and Research Centers, Clinical Diagnostics, Drug Discovery, Monitoring and Screening

Regional Segmentation North America U.S., Canada Europe Germany, France, Italy, U.K., Spain, Russia, Netherlands Asia-Pacific Japan, China, India, Australia, Singapore Latin America Brazil, Mexico Rest-of-the-World Kingdom of Saudi Arabia (K.S.A.), U.A.E., Palestine, Algeria

Cross Segmentation North America Genetic Testing Type (Oncology Genetic Testing, Cardiology Genetic Testing, Neurology Genetic Testing, Newborn Screening, NIPT, Rare Disease Testing, Direct to Consumer Testing Europe Genetic Testing Type (Oncology Genetic Testing, Cardiology Genetic Testing, Neurology Genetic Testing, Newborn Screening, NIPT, Rare Disease Testing, Direct to Consumer Testing Asia-Pacific - Genetic Testing Type (Oncology Genetic Testing, Cardiology Genetic Testing, Neurology Genetic Testing, Newborn Screening, NIPT, Rare Disease Testing, Direct to Consumer Testing Latin America Genetic Testing Type (Oncology Genetic Testing, Cardiology Genetic Testing, Neurology Genetic Testing, Newborn Screening, NIPT, Rare Disease Testing, Direct to Consumer Testing Rest-of-the-World Genetic Testing Type (Oncology Genetic Testing, Cardiology Genetic Testing, Neurology Genetic Testing, Newborn Screening, NIPT, Rare Disease Testing, Direct to Consumer Testing

Growth Drivers Rising Prevalence of Genetic Disorders Increasing Prevalence of Various Types of Cancer, Globally Increasing Research Funding in the Field of Genomics

Market Challenges Expensive Sequencing Procedures and Their Applications in Medical Treatments High Capital Requirement Hampering the Expansion of Global Reach Stringent Regulatory Standards

Market Opportunities Technological Advancements for Exome Sequencing Rise of Direct-to-Consumer (DTC) Testing Services Massive Scope for Adoption of NGS-Based in Emerging Nations

Key Companies ProfiledAgilent Technologies, Inc., Ambry Genetics, Beijing Genomics Institute (BGI), CENTOGENE AG, Eurofins Scientific SE, F. Hoffmann-La Roche Ltd, Inc. Illumina, Inc. , Laboratory Corporation of America Holdings, Myriad Genetics, Inc., PerkinElmer, Inc., Quest Diagnostics Incorporated, Thermo Fisher Scientific Inc.

Key Questions Answered in this Report: What are the possible long-term and short-term impacts of hereditary genetic testing on the human health continuum? What are the major market drivers, challenges, and opportunities in the hereditary genetic testing? What are the key development strategies which are being implemented by the major players in order to sustain in the competitive market? What are the key regulatory implications in the developed and developing regions for the global hereditary genetic testing market? How are service-based companies impacting the growth of the global hereditary genetic testing industry and further shaping up future trends? How each segment of the market is expected to grow during the forecast period from 2020 to 2030? Who are the leading players with significant offerings to the global hereditary genetic testing market? What is the expected market dominance for each of these leading players? Which companies are anticipated to be highly disruptive in the future, and why? What are the needs that are yet to be met by the global hereditary genetic testing market with respect to the application area? What are the dynamics of various application areas and countries are impacting the global hereditary genetic testing market? What are the new market opportunities of various technologies influencing the growth of the global hereditary genetic testing market?

Market OverviewThe hereditary genetic testing has grown significantly since the technology was first commercialized, but it is important to quantify that growth and describe future trends.The genome testing industry is proliferating, and its growth is expected to continue at its torrid pace.

However, there are significant challenges that may dampen future growth if not addressed.

Our healthcare experts have found hereditary genetic testing to be one of the most rapidly evolving technologies, and the global market for hereditary genetic testing is predicted to grow at a CAGR of 13.59% over the forecast period of 2020-2030.

The unmet clinical needs for better tools to predict, diagnose, treat, and monitor disease are acting as significant factors driving the growth of sequencing industry. Other factors driving the growth include the increased understanding of the molecular basis of disease, patient demand, industry investment, and regulations that allow marketing of tests without FDA approval.

Despite rapid advanced sequencing industry growth, there are several key issues that are needed to be addressed to facilitate future growth.The relatively high total costs of delivering sequencing test results compared with other technology platforms, and limited coverage by payers, are the key challenges to the growth of this industry.

Whole genome and exome sequencing remain relatively costly requiring initial equipment investment, specialized workforce requirements, and time-intensive variant interpretation.

Within the research report, the market is segmented on the basis of oncology genetic testing, cardiology genetic testing, neurology genetic testing, product, sample, application area, and region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.

Competitive LandscapeThe exponential rise in the application of next generation sequencing on the global level has created a buzz among companies to invest in the products and services of whole genome and exome sequencing. Due to the diverse product portfolio and intense market penetration, whole genome and exome has been a pioneer in this field and been a significant competitor in this market.

On the basis of region, North America holds the largest share, due to improved healthcare infrastructure, rise in per capita income, and improvised reimbursement policies in the region. Apart from this, Latin America and the Asia-Pacific region are anticipated to grow at the fastest CAGR during the forecast period.

Countries Covered North America U.S. Canada Europe Germany France Italy U.K. Spain Russia Netherlands Rest-of-Europe Asia-Pacific China Japan India Australia Singapore Rest-of-APAC Latin America Brazil Mexico Rest-of-Latin America Rest-of-the-World (RoW)Read the full report: https://www.reportlinker.com/p05930381/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Read the original:
Global Hereditary Genetic Testing Market: Focus on Product, Sample, Technology, Genetic Testing Type, Application Area, Country Data (16 Countries),...

Read More...

Researchers Discover Genetic Variants Linked to Type 2 Diabetes – HealthITAnalytics.com

Wednesday, July 8th, 2020

July 08, 2020 -In the largest study of its kind, researchers discovered hundreds of novel genetic variants linked to type 2 diabetes, potentially improving care for millions living with this disease.

A team from the Perelman School of Medicine at the University of Pennsylvania and the Veterans Health Administrations (VHA) Corporal Michael J. Crescenz Veterans Affairs Medical Center (CMCVAMC) examined the genes of more than 200,000 people around the world with type 2 diabetes.

In addition to uncovering new genetic variants linked to the condition, researchers identified gene variants that vary by ethnicity, as well as variants tied to conditions related to type 2 diabetes like coronary heart disease and chronic kidney disease.

The group used data from the worlds largest biobank, the Million Veteran Program (MVP) in the VHA, as well as data from the DIAGRAM Consortium, the UK Biobank, the Penn Medicine Biobank, and Biobank Japan. Researchers analyzed a study population of 1.4 million people around the world, of whom almost 230,000 had type 2 diabetes.

The team then broke down the genetic makeup of those hundreds of thousands with type 2 diabetes and found 558 independent genetic variants that are differentially distributed between people with and without type 2 diabetes. Twenty-one of these variants were specific to European ancestry while seven were specific to African American ancestry. Of the 558 variants found, 286 had never been discovered.

Researchers set out to discover if certain genetic variants among this group of people could be linked to specific type 2 diabetes-related conditions.

Ultimately, three were linked to coronary heart disease, two to acute ischemic stroke, four to retinopathy, two to chronic kidney disease, and one to neuropathy, saidMarijana Vujkovic, PhD, a biostatistician at both the Perelman School of Medicine at the University of Pennsylvania, VHAs CMCVAMC and a co-leader for the VHAs national MVP Cardiometabolic Working Group.

Building on this research, the scientific community can assess which of the surrounding genes nearby the identified genetic variants is likely to be the causal gene that alters the risk of type-2 diabetes, and that could lead to early interventions to limit controllable risks of developing the condition.

While the researchers found many genetic variants in people with type 2 diabetes, no one variant was labeled as the worst or most dangerous.

However, just like heart disease, schizophrenia, or obesity, it is the accumulation of a large number of these variants that can add up to a considerable increase in risk, said co-senior authorBenjamin F. Voight, PhD, an associate professor of Systems Pharmacology and Translational Therapeutics at Penn, and a co-leader for the VHAs national MVP Cardiometabolic Working Group.

We hope this study can not only help find that subset of patients with substantial risk, but also to motivate new, future studies for treatments based on these findings.

Knowing more about the genetic variants linked to type 2 diabetes could help identify potential therapeutic targets for type 2 diabetes. Researchers also noted that this information could help guide treatment plans for people with the disease who may be susceptible to specific diabetes complications.

Going forward, the researchers plan to conduct a long-term examination of how genetics influence disease progression among patients with type 2 diabetes and associated metabolic disorders. The group is also leveraging the list of newly-discovered genes to investigate medication interactions.

Knowing the genetic susceptibility for diabetes complications in a patient already diagnosed with type-2 diabetes, for example through a cumulative genetic risk score, could help guide that patients care, said co-senior-authorKyong-Mi Chang, MD, a professor of Medicine at Penn, Associate Chief of Staff for Research at VHAs CMCVAMC and the Co-PI for the VHAs MVP Merit Award that supported this work.

As clinicians, we hope that these findings can ultimately be applied to improve the health outcomes for our patients including veterans.

Follow this link:
Researchers Discover Genetic Variants Linked to Type 2 Diabetes - HealthITAnalytics.com

Read More...

Genetic Support Foundation of Olympia Announces New Resource for Hereditary Cancer Risk – ThurstonTalk

Wednesday, July 8th, 2020

Submitted by Genetic Support Foundation

For those who have received a positive result after genetic testing for pathogenic variants that significantly increase cancer risk, a new resource is available for connecting with others who are in a similar situation.

Positive Results is a new Facebook group for support and resources around hereditary cancer risk. The group was formed by Genetic Support Foundation (GSF) to help connect the hereditary cancer community in a welcoming, digital environment. The group is administered by professionals and patients connected to GSF and aims to provide expert educational materials and to host meaningful discussions around all facets of hereditary cancer. The forum is open to those with positive results, caregivers and loved ones of those with positive results, and those in the medical community who are familiar with the unique needs of someone with hereditary cancer risk. It is not intended to replace any medical care or advice.

When patients receive a positive result for hereditary cancer risk, we often point them to external resources for support. While these resources are well-known and respected, we found that many patients want to connect with others who are going through a similar experience, explains Katie Stoll, executive director of GSF. With this new forum, we can offer people accurate information in a safe and welcoming space with support that goes beyond the counseling appointment.

Inherited pathogenic genetic variants, sometimes called mutations, play a major role in about 5 to 10 percent of all cancers. Better-known pathogenic gene variants include BRCA1 and BRCA2, which increases risk of breast and ovarian cancers, among others. But with mutations in specific genes being linked to more than 50 hereditary cancer syndromes, the hope is that all those affected will feel welcome to join the group.

Carrying the knowledge of being predisposed to cancer can be a burden, or it can be empowering, and often its both, says Nikki McCoy, who will help as an admin on the page, and who is positive for a BRCA1 gene variant. We hope that members feel empowered after visiting the group and that they feel supported and not alone. Community-building can be extremely healing and helpful.

The group is also welcoming of those who may not have had genetic testing but have a strong family history of cancer.

Women and men both have a 50 percent chance to inherit and pass down pathogenic variants. Almost all people who have a pathogenic variant will have a parent who also carries it. Many people who have a pathogenic variant and develop cancer do so at younger ages than the general population.

For more information, visit the Facebook group.

Go here to see the original:
Genetic Support Foundation of Olympia Announces New Resource for Hereditary Cancer Risk - ThurstonTalk

Read More...

Parkinson’s Foundation Shares Early Results of PD GENEration Study – Parkinson’s News Today

Wednesday, July 8th, 2020

Preliminary results from the PD GENEration study demonstrate that comprehensive genetic testing and counseling, and the identification of rare genetic mutations linked to Parkinsons disease, is feasible for the Parkinsons community at large.

Launched in 2019through theParkinsons Foundation and supported partly by Biogen, the study offers free genetic testing to Parkinsons patients, as well as free genetic counseling to help them understand their results.

Although an estimated 15% of Parkinsons cases might stem from genetic mutations, testing for clinically relevant genes remains uncommon.

Since launch, the PD GENEration study has tested at least 291 people, 52 of whom tested positive for a Parkinsons-related mutation. This translates to a 17% detection rate, which is slightly higher than that estimated in the scientific literature.

According to a press release from the Parkinsons Foundation, PD GENEration researchers expect the detection rate to rise as more people with Parkinsons get tested.

These interim findings represent the cornerstone in our success to lay the foundation for precision medicine in Parkinsons disease, said James Beck, chief scientific officer of the Parkinsons Foundation, in the same press release. By better understanding the genetic implications for people with [Parkinsons], scientists will be able to move research and treatments forward towards a cure.

The exact causes of Parkinsons remain unknown. Although scientists believe that both genetic and environmental factors contribute to the condition, the extent to which each does so remains unclear. Expanding genetic testing may prove an effective way to shed light on that topic.

PD GENEration tests for seven genes with known Parkinsons associations: GBA(glucocerebrosidase beta),LRRK2(dardarin),PRKN(Parkin),PINK1(PTEN induced putative kinase 1),PARK7(DJ-1),VPS-35,andSNCA(alpha-synuclein).

Testing for mutations in all of these genes is neither always available nor always covered by insurance. At-home kits are both limited in which changes they can detect and they cannot detect new mutations, which is a major goal of PD GENEration.

Some participants tested have shown extremely rare mutations, with some individuals even carrying multiple Parkinsons-associated mutations. This information will contribute to a better understanding of the condition and should help in assessing the impact that certain mutations have on Parkinsons progression and outcomes.

Although a genetic cause is unlikely to be found in most Parkinsons patients, understanding the genetics of the condition better will improve the knowledge of its underlying biology, which will contribute to finding new therapeutic targets that could benefit many more people living with Parkinsons.

This study is critical for the entire [Parkinsons] community, said John L. Lehr, President and CEO of the Parkinsons Foundation. PD GENEration participants can now arm themselves with more information about their specific diagnosis while helping scientists advance [Parkinsons] research. We will continue to expand the PD GENEration study to better serve the [Parkinsons] community while moving research forward.

The PD GENEration study is currently in a pilot phase. The Parkinsons Foundation plans to expand testing sites to enroll up to 15,000 participants by late this year.

The pilot program experienced delays related to the COVID-19 pandemic, which caused a temporary suspension in testing. Although this means the program has fallen shy of its 600 anticipated participants so far, the foundation now is preparing a telemedicine-based approach, in which participants may use at-home genetic testing kits.

Virtual genetic counseling will be made available in English and Spanish. More information about where to find sites that are actively enrolling is available here.

Forest Ray received his PhD in systems biology from Columbia University, where he developed tools to match drug side effects to other diseases. He has since worked as a journalist and science writer, covering topics from rare diseases to the intersection between environmental science and social justice. He currently lives in Long Beach, California.

Total Posts: 208

Ana holds a PhD in Immunology from the University of Lisbon and worked as a postdoctoral researcher at Instituto de Medicina Molecular (iMM) in Lisbon, Portugal. She graduated with a BSc in Genetics from the University of Newcastle and received a Masters in Biomolecular Archaeology from the University of Manchester, England. After leaving the lab to pursue a career in Science Communication, she served as the Director of Science Communication at iMM.

See original here:
Parkinson's Foundation Shares Early Results of PD GENEration Study - Parkinson's News Today

Read More...

PRC1 Plays a Role in Genetic Errors and Cancer – Technology Networks

Wednesday, July 8th, 2020

An over-abundance of the protein PRC1, which is essential to cell division, is a telltale sign in many cancer types, including prostate, ovarian, and breast cancer. New research, published online today inDevelopmental Cell, shows that PRC1 acts as a viscous glue during cell division, precisely controlling the speed at which two sets of DNA are separated as a single cell divides. The finding could explain why too much or too little PRC1 disrupts that process and causes genome errors linked to cancer.

PRC1 produces a viscous frictional force, a drag that increases with speed, said Scott Forth, an assistant professor of biological sciences and member of theCenter for Biotechnology and Interdisciplinary Studiesat Rensselaer Polytechnic Institute. The friction it produces is similar to that of water if you try to move your hand through water slowly, you move easily, but if you push your hand fast, the water pushes back hard.

At the nitty-gritty level of DNA, motor proteins, and microtubules, biology takes its cue from physics. During the mitotic stage of cell division, a single cell must copy its DNA into two identical sets, and then rapidly and efficiently pull that DNA apart into two new daughter cells. Its a physical act, and the cellular structure that does it, the mitotic spindle, is a machine that uses mechanical forces push, pull, and resistance to complete the task.

We think the force PRC1 produces is integrating and dampening out cellular motions as the DNA is separated so that ultimately, you get the correct rate of chromosome segregation, Forth said. But if the process goes awry, the cells end up working with the wrong instruction manual, which can lead to the uncontrollable growth of cancer.

The Forth lab examines the physical forces exerted by components of cellular structures like the mitotic spindle. The spindle is formed when two centrosomes, take a position on opposite sides of the two newly created, and hopefully identical, sets of chromosomes massed near the center of the cell. A dense network of microtubules extends from the centrosomes, forming a cage that surrounds and connects the chromosomes. Then the microtubules aided by millions of proteins and motor proteins begin to shorten and slide, pulling the chromosomes toward the centrosomes, until the two sets have been separated.

PRC1 is a cross-linker, a long, springy molecule with a head at either end that links two microtubules along their length. Near the center of the mitotic spindle, large quantities of PRC1 link groups of microtubules into bundles.

Forths team created a controlled version of the microtubule sliding mechanism in the lab and used an optical trapping technique to measure the frictional force PRC1 exerts between the sliding microtubules. Optical trapping relies on a tightly focused laser beam which attracts an object in this case, a miniscule polystyrene bead attached to the microtubule. The researchers use the laser beam to pull on the bead similar to the tractor beam of science fiction and convert the shift in refracted light as the bead resists the pull of the trap into a direct measure of force.

The team also tagged PRC1 with a fluorescent molecule, allowing them to observe its shifting movement and distribution as the microtubules were pulled apart. They used total internal reflection fluorescence microscopy to collect images of the experiment while simultaneously recording the forces.

Forth and his colleagues found that, as more of the protein is added into the system, the microtubules meet more resistance as they move faster. Essentially, PRC1 behaves like a glue holding the cell together.

Like a lot of biological processes, its a bit of a Goldilocks problem, Forth said. If you dont have this protein, youre in trouble, because the cell fails at division. If you have too much, we think that it gums up the works and holds everything together too much, which may be how this protein is linked to cancer. Theres a sort of sweet spot in healthy cell division, where theres just the right amount controlling the rates carefully and precisely.

This research reveals the inner workings of a fundamental mechanism of biology, providing knowledge that better positions us to defeat cancer, said Curt Breneman, dean of the School of Science. Its a carefully and beautifully designed study, the results of which have created a foundation on which future anti-cancer strategies can be built.

Reference: Gaska, et al. (2020). The mitotic crosslinking protein PRC1 acts as a mechanical dashpot to resist microtubule sliding. Developmental Cell. DOI:https://doi.org/10.1101/2019.12.12.874529

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

See the rest here:
PRC1 Plays a Role in Genetic Errors and Cancer - Technology Networks

Read More...

Expert Advises Genetic Profiling in MCL Can Be a Useful Tool in Treating The Disease – Curetoday.com

Wednesday, July 8th, 2020

We learned from previous prospective studies (that) using chemoimmunotherapy for those patients with TP53 aberrations, the survival data compared with others that do not harbor this mutation are much less favorable, said Dr. Jia Ruan.

In a recent interview with CUREs sister publication, OncLive, Ruan, of Weill Cornell Medicine, discussed what characteristics make up aggressive forms of MCL, as well as how those characteristics play a role in treating the disease.

CURE: What are some of the features that are characteristic of aggressive MCL, and the current prognosis for those patients?

Jia Ruan: One that is quite important is a genetic mutation profile. We pay a lot of attention to a genetic aberration called P53. It could come as mutations; it could come as deletions. Generally speaking, we group them together as an aberration, but we do know that mutation weighs more heavily in the outcome prediction. And we learned from previous prospective studies (that) using chemoimmunotherapy for those patients with TP53 aberrations, the survival data compared with others that do not harbor this mutation are much less favorable.

We're talking about overall survival less than two years compared with others, which could be more than a decade. That makes a huge difference, right? It doesn't mean that we won't offer chemoimmunotherapy, but we think very actively from the (beginning). What are the backup options for those patients should they not respond to chemoimmunotherapy or relapse early on? Should we be thinking about more smart medicine with targeted therapy that could be incorporated in the initial therapy of those patient cohorts?

Considering all the treatment options that are currently available, what does the current risk stratification paradigm look like?

The treatment, or management, decisions would have to factor into the mantle cell lymphoma disease feature, which are objective features that are reflected on by clinical parameters, such as mutational profile and morphological features that let us know whether it's going to be a conventional form of mantle cell lymphoma vs. those that are quite aggressive and generally have high resistance or a very short duration with even high-intensity chemotherapy.

One could also think about (the) objective of the patients who actually harbor the disease. (For instance), what is their preference? Is it a short-defined duration of chemoimmunotherapy as tolerated, which certainly we can dial up the intensity with high dose cytarabine vs. autologous stem cell transplant and maintenance treatment vs. outpatient-based chemoimmunotherapy with maintenance vs. options that they can take pills at home with less frequent acute medical care?

I think all of those become factors, and I think that the decisions would be made easier if we actually have data to compare what the efficacy (and) side effect/outcome data (are), comparing chemoimmunotherapy vs. novel agents in combination or introducing novel agents into chemotherapy, can we lengthen their intensity or shorten the duration? And what are the biomarkers that can help us make those determinations? Could this be something like a minimal residual disease measurement, or can we base our choice of treatment intensity or duration based on the response assessment, not only on conventional imaging studies, clinical parameter, but also novel biomarkers, which can detect a good response earlier, or a potential relapse also much earlier.

What is your take-home message when reviewing state-of-the-art treatment options for patients with aggressive MCL?

When we evaluate patients with mantle cell lymphoma, we have to apply the most up to date precision medicine method, if possible, looking at not only pathology diagnosis, but also features that help us to determine the risk category, whether it's an aggressive form vs. a conventional form where people can watch and wait a little bit and apply the sequencing data or cytogenetic efficient analysis and incorporating fairly simple immunohistochemical markers such as KI-67.

I think we do that quite routinely in our academic practice. And then I think to have a very comprehensive discussion with patients regarding treatment options, both from a conventional chemoimmunotherapy-based treatment vs. experimentation with clinical trials, which there are plenty of options that introduce novel agency in the frontline setting. Participation in clinical trials is really instrumental in pushing the envelope and ... it's beneficial for all parties involved if adequate consideration can be put into a very, very well-designed clinical trial.

See more here:
Expert Advises Genetic Profiling in MCL Can Be a Useful Tool in Treating The Disease - Curetoday.com

Read More...

Direct-to-consumer Genetic Testing Market Patents Analysis 2019-2036 – Cole of Duty

Wednesday, July 8th, 2020

The global Direct-to-consumer Genetic Testing Marketplace gives detailed Evaluation about all of the important aspects related to the marketplace. The analysis on global Direct-to-consumer Genetic Testing market, offers profound insights about the Direct-to-consumer Genetic Testing market covering all of the crucial characteristics of the market. Moreover, the report provides historical information with prospective prediction over the forecast period. Various important aspects like market trends, revenue development patterns market shares and supply and demand are included in almost all the market research report for every single business. Some of the vital aspects analyzed in the report includes market share, production, key regions, revenue rate as well as key players.

The study of different sections of the global market are also Covered in the research report. Along with that, for the prediction periods conclusion of variables such as market size and the competitive landscape of this sector is assessed in the report. On account of the rising globalization and digitization, there are new tendencies coming to the marketplace daily. The research report provides the in-depth analysis of all of these tendencies.

Get PDF Sample Copy of this Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) @ https://www.researchmoz.com/enquiry.php?type=S&repid=2644650&source=atm

In addition, the Direct-to-consumer Genetic Testing market report also supplies the Latest tendencies in the international Direct-to-consumer Genetic Testing market with the assistance of primary as well as secondary research methods. Also, the analysis report on Direct-to-consumer Genetic Testing marketplace gives a wide evaluation of the market which includes market review, manufacturing, manufacturers, dimensions, price, value, growth rate, income, deals, export, consumption, and sales revenue of this global Direct-to-consumer Genetic Testing market. On the other hand, the Direct-to-consumer Genetic Testing market report also studies the industry standing for the prediction period. Nevertheless, this can help to increase the advertising opportunities throughout the world in addition to major market providers.

Regional and Country-level AnalysisThe report offers an exhaustive geographical analysis of the global Direct-to-consumer Genetic Testing market, covering important regions, viz, North America, Europe, China, Japan, Southeast Asia, India and Central & South America. It also covers key countries (regions), viz, U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, UAE, etc.The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by each application segment in terms of revenue for the period 2015-2026.Competition AnalysisIn the competitive analysis section of the report, leading as well as prominent players of the global Direct-to-consumer Genetic Testing market are broadly studied on the basis of key factors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on price and revenue (global level) by player for the period 2015-2020.On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Direct-to-consumer Genetic Testing market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Direct-to-consumer Genetic Testing market.The following players are covered in this report:23andMeMyHeritageLabCorpMyriad GeneticsAncestry.comQuest DiagnosticsGene By GeneDNA Diagnostics CenterInvitaeIntelliGeneticsAmbry GeneticsLiving DNAEasyDNAPathway GenomicsCentrillion TechnologyXcodeColor GenomicsAnglia DNA ServicesAfrican AncestryCanadian DNA ServicesDNA Family CheckAlpha BiolaboratoriesTest Me DNA23 MofangGenetic HealthDNA Services of AmericaShuwen Health SciencesMapmygenomeFull GenomesDirect-to-consumer Genetic Testing Breakdown Data by TypeDiagnostic ScreeningPrenatal, Newborn Screening, and Pre-Implantation DiagnosisRelationship TestingDirect-to-consumer Genetic Testing Breakdown Data by ApplicationOnlineOffline

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.researchmoz.com/enquiry.php?type=E&repid=2644650&source=atm

The Direct-to-consumer Genetic Testing market report provides helpful insights for Every established and advanced players across the world. Additionally the Direct-to-consumer Genetic Testing marketplace report provides accurate analysis for the shifting competitive dynamics. This study report includes a whole analysis of future growth concerning the evaluation of this mentioned prediction interval. The Direct-to-consumer Genetic Testing marketplace report provides a thorough study of the technological growth outlook over time to be aware of the industry growth rates. The Direct-to-consumer Genetic Testing market report also includes innovative analysis of the massive number of unique factors that are fostering or operating as well as regulating the Direct-to-consumer Genetic Testing marketplace development.

A systematized methodology can be used to create a Study on the Global Direct-to-consumer Genetic Testing Sector. For the analysis of market on the terms of research Approaches, these strategies are useful. All the Information Regarding the Products, makers, vendors, clients and even more is covered in research reports. Various important factors like market trends, earnings Growth patterns market stocks and supply and demand are contained in almost all The market research report for every single business. Adaptation of new thoughts and Accepting the latest tendencies are a few the reasons for any markets growth. The Global Direct-to-consumer Genetic Testing market research report gives the deep understanding about the Areas in which the marketplace is impactful.

You can Buy This Report from Here @ https://www.researchmoz.com/checkout?rep_id=2644650&licType=S&source=atm

Read the rest here:
Direct-to-consumer Genetic Testing Market Patents Analysis 2019-2036 - Cole of Duty

Read More...

Pan-Cancer Consortium Moves to Clarify and Promote Consistent Use of Common Terms for Biomarker and Germline Genetic Testing – BioSpace

Wednesday, July 8th, 2020

WASHINGTON, July 7, 2020 /PRNewswire/ --A LUNGevity Foundation-led consortium of 41 leading patient advocacy organizations, professional societies, and industry partners has published a white paper detailing recommendations for the use of testing terminology in precision medicine for patient education throughout the cancer community. Use of consistent language will significantly improve patient awareness and understanding of potentially lifesaving testing options available for both new cancer diagnoses and progression or recurrence of disease.

Research shows that despite widespread acceptance of the importance of testing, actual testing rates lag far behind best-practice recommendations for both biomarker testing for somatic (acquired) mutations and other biomarkers, and for germline genetic testing for identifying germline (inherited) mutations (also known as variants). Analysis by The Consistent Testing Terminology Working Group (Working Group) indicates that language disparity is a primary obstacle to patient communication with providers about testing for their specific cancer type. Further, development of consistent language can increase patient understanding and communication, facilitate shared decision making, support value-based care, and assure concordance in policy development.

The Working Group is a consortium of 20 cancer patient advocacy groups representing solid tumor and hematologic malignancies, three professional societies, and 18 pharmaceutical and diagnostic companies and testing laboratories. Over the course of many years, multiple activities, led by numerous individual patient advocacy organizations and professional societies, have developed the groundwork for this effort. The Working Group has launched a multi-faceted dissemination and communications effort to ensure that its recommendations and supporting materials are widely available among all key stakeholders within the cancer ecosystem, including providers, patient advocacy organizations, guidelines agencies, payers, and policymakers.

In developing its recommendations, the Working Group, first convened in 2019 by LUNGevity Foundation, identified 33 terms related to biomarker, genetic, and genomic testing that were being used in patient education and clinical care within the different cancer communities. In many cases, multiple terms were used to describe the same test. Various testing modalities, the source of testing samples, and the multiplicity of gene mutations currently identifiable by testing were contributing factors in this often-confusing overlap.

In the final analysis, three umbrella descriptor terms emerged as recommendations from the Working Group's milestone exploration: "Biomarker testing"was selected as the preferred term for tests that identify characteristics, targetable findings, or other test results originating from malignant tissue and blood; "genetic testing for an inherited mutation" and "genetic testing for inherited cancer risk" were selected as consensus terms for tests used to identify germline (inherited) mutations.

"Far too many patients across all cancer types are still missing out on essential tests for biomarkers and inherited mutations indicating cancer risk," said Michelle Shiller, DO, AP/CP, MGP, Co-Medical Director of Genetics at Baylor Sammons Cancer Center and Staff Pathologist at Baylor University Medical Center. "With rates of biomarker testing and genetic testing for an inherited mutation at sub-optimal levels for numerous patient populations, patients are not benefiting from biomarker-directed care or not learning about their inherited cancer risk. Confusion around testing terms is a driving factor in this undertesting and ultimately has a detrimental impact on patient care."

Adds Nikki Martin, Director of Precision Medicine Initiatives at LUNGevity Foundation, "When someone is diagnosed with cancer, they're swept into a whirlwind of bewildering words and complex, pressing decisions. Our Working Group's goal is to help calm that storm of confusion with clear and consistent language that facilitates communication and medical decision-making. A unified voice and message from providers, industry, and the patient advocacy community about testing is absolutely vital to optimal cancer care."

An abstract on the Working Group's recommendations was published in May 2020 as part of the American Society of Clinical Oncology (ASCO) Annual Meeting Virtual Library.

The White Paper can be viewed in its entirety atwww.CommonCancerTestingTerminology.org.

Working Groupparticipating organizations include:

Patient Advocacy: CancerCare; Cancer Support Community;The CholangiocarcinomaFoundation;Clearity Foundation; Colorectal Cancer Alliance; Fight CRC; FORCE(Facing Our Risk of Cancer Empowered); International Cancer Advocacy Network; Leukemia & Lymphoma Society; The Life Raft Group; Lymphoma Research Foundation; Living Beyond Breast Cancer; Lung Cancer Action Network (LungCan); LUNGevity Foundation; National Lung Cancer Roundtable(American Cancer Society); PanCAN; Personalized Medicine Coalition; Prostate Cancer Foundation; Ovarian Cancer Research Alliance (OCRA); Sharsheret(The Jewish Breast & Ovarian Cancer Community);and Susan G. Komen.

Professional Societies: Association of Community Cancer Centers(ACCC);Association for Molecular Pathology(AMP); and National Society of Genetic Counselors(NSGC).

Industry Partners: Abbvie; Amgen;AstraZeneca; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Caris Life Sciences; Eli Lilly and Company; Foundation Medicine; Genentech;GlaxoSmithKline (GSK); Novartis; Myriad Women's Health; NeoGenomics; Pfizer; Personal Genome Diagnostics (PGDx); andThermo Fisher Scientific.

About LUNGevity Foundation

LUNGevity Foundation is the nation's leading lung cancer organization focused on improving outcomes for people with lung cancer through research, education, policy initiatives, and support and engagement for patients, survivors, and caregivers. LUNGevity seeks to make an immediate impact on quality of life and survivorship for everyone touched by the diseasewhile promoting health equity by addressing disparities throughout the care continuum. LUNGevity works tirelessly to advance research into early detection and more effective treatments, provide information and educational tools to empower patients and their caregivers, promote impactful public policy initiatives, and amplify the patient voice through research and engagement. The organization provides an active community for patients and survivorsand those who help them live better and longer lives.

Comprehensive resources include a medically vetted and patient-centric website, a toll-free HELPLine for support, the International Lung Cancer Survivorship Conference, and an easy-to-use Clinical Trial Finder, among other tools. All of these programs are to achieve our visiona world where no one dies of lung cancer. LUNGevity Foundation is proud to be a four-star Charity Navigator organization.

About Lung Cancer in the US

Please visit http://www.LUNGevity.orgto learn more.

View original content to download multimedia:http://www.prnewswire.com/news-releases/pan-cancer-consortium-moves-to-clarify-and-promote-consistent-use-of-common-terms-for-biomarker-and-germline-genetic-testing-301088874.html

SOURCE LUNGevity Foundation

Read more here:
Pan-Cancer Consortium Moves to Clarify and Promote Consistent Use of Common Terms for Biomarker and Germline Genetic Testing - BioSpace

Read More...

DNA the genetic crime solver – TheSpec.com

Wednesday, July 8th, 2020

She collected every little tiny bit of ash from the bottom of the animal incinerator into a dust pan.

She wanted Tim Bosmas family to have all that was left of him.

As Hamilton Police Services most senior forensics officer, Sgt. Annette Huys also hoped DNA testing could confirm these were Tims remains.

Deoxyribonucleic acid. The recipe for humankind. The solver of crimes. The holy grail of conviction. Or exoneration.

Forensic DNA science in Canada is an evolving intersection of biology, the law and ethics. Even as some scientists perfect current DNA capabilities, others are forging further, finding new ways to analyze the basic human building blocks. These lab-coated pioneers are forcing police, lawyers, academics, politicians and human rights advocates to keep up.

The United States has plunged into uncharted and often controversial frontiers.

Just a few days ago, DNA cemented a new application in the U.S. as the Golden State Killer pleaded guilty to 13 counts of first-degree murder in California. Joseph DeAngelo a former cop whose rape and murder spree spanned the 1970s and 80s was the first person arrested thanks to police submitting crime scene DNA into a public genealogy database.

The 74-year-old is one of the most prolific predators in modern history and the DNA sleuthing in his case will change criminal investigations forever.

Canada is taking a measured approach to DNA advances. Some may see that caution as smart and careful. Others may be frustrated that killers and rapists are on the loose while we debate and discuss.

Should police use public genealogy databanks to access DNA profiles to solve crimes? Can reverse-engineered mugshots created from crime scene DNA point investigators toward innocent suspects? Will categorizing suspects by their ancestry lead to racial profiling?

Huys, who just recently left the forensics unit, is grateful her work allowed her to focus on science as she honed in on bones and fluids and their underlying DNA.

Im glad at scenes that we have a lot of work to do. It prevents me from dwelling on the horrible reality of why I am there.

Sometimes, she was powerfully reminded her work is ultimately about the human element. Like in February 2016, in the packed Hamilton courtroom where Tims killers were on trial.

As she stepped into the witness box, Huys looked to the front row and saw Tims family for the first time. She testified to sifting through that incinerator, called The Eliminator, cataloguing bone fragments.

Tims mother fled the courtroom sobbing. Huys heart broke for her, as she explained to the jury that two scorched bones were examined by forensic scientists. But the extreme heat they were exposed to made a DNA profile impossible.

Other DNA evidence, however, drew direct links between the victim and the murderers. For instance, a glove that had DNA belonging to Tim and one of his killers. Or the one in 18 quadrillion chance that blood on Tims truck (found in a driveway connected to one of his killers) came from someone other than him.

After five days of giving evidence, Huys was done. In the courthouse hall, Tims dad approached her.

I just want to thank you, said Hank Bosma. That must have been hard for you.

It was. Because forensic DNA is never just about science.

Three kinds of DNA

DNA is the genetic blueprint of life and is packaged into paired structures known as chromosomes. One from each pair is contributed by an individuals biological mother and the other by his/her biological father. With the exception of identical twins, no two individuals have exactly the same DNA. Centre of Forensic Sciences (CFS)

Huys lists three kinds of DNA:

First, anything that oozes out of the human body.

Next, handler DNA. That is left behind when an ungloved person touches an object. A baseball bat found at a homicide might have a blood stain from the victim. But its grip may also have DNA from someones hands. Scientists and police must work together to determine if the DNA on the grip came from a suspect.

Then there is wearer DNA. It is left inside clothing. Maybe a balaclava or gloves.

Wearer and handler DNA testing wasnt done when Huys started her career. Now, its routine.

In courtrooms across Ontario, biologists from Torontos CFS testify about Smarties.

The Smartie analogy goes like this: A Smartie candy weighs a gram. Now chop it into 1,000 equal-sized pieces. Then take one of those pieces and chop that into 1,000 pieces. Finally, take one of those pieces and cut it into 1,000 pieces.

One of those segments measures 1/billionth of a gram and that amount of DNA can be detected, analyzed and profiled. In the most urgent cases such as a serial predator at large results can be available in 24 hours.

That tiny amount of DNA could be enough evidence to put someone in prison for life on a first-degree murder charge.

DNA: a breakthrough in the courtroom

DNA was discovered in 1953 and was first used in a homicide trial in Britain in 1986. Canadas initial attempt to use DNA in a criminal case failed.

In 1988, samples taken from seven victims of what appeared to be a serial rapist in Alberta were insufficient to be tested by the clunky new technology that required substantial amounts of blood, semen or saliva and could take 10 weeks to process.

The accused, James Parent, was acquitted on all counts. (Though 20 years later DNA would convict him of another sexual assault.)

In 1989, DNA got another chance in the courtroom. Paul McNally, a suspect in the rape of an Ottawa woman, denied he was responsible. Yet he agreed to supply hair, blood and saliva samples to police.

Testing showed he was almost certainly the contributor of semen found on the victims nightgown.

When the trial judge ruled the DNA results were admissible, McNally changed his plea to guilty.

DNA was on its way to becoming a mainstay of the Canadian judicial system.

In 1995, new federal legislation granted Canadian police the right to obtain DNA from offenders convicted of serious crimes. It became mandatory for criminals convicted of murder and sexual assault, for instance, to submit DNA samples. Five years later, the RCMP established the National DNA Data Bank (NDDB). It has now assisted in more than 62,000 criminal investigations.

The NDDB says its goals are to link crime scenes across jurisdictional lines, help identify or eliminate suspects and determine whether a serial offender has been involved in certain crimes.

Offenders entered into the databank are part of the Crime Offender Index. DNA from crime scenes is entered into the Crime Scene Index.

The two categories are constantly and automatically compared. Matches or hits are reported to the investigating police officer.

The type of investigation most frequently assisted by the NDDB by a long shot is break and enters. The databank has had upwards of 28,000 offender hits for break-ins. DNA is routinely collected from break-ins and from those convicted of breaking into houses. For murders, that number is 4,028.

In 2018, two new criminal DNA indexes were added. The Victims Index holds DNA profiles from victims of crime and could help police link crime scenes and subsequently identify serial offenders.

For instance, rape kit swabs from a series of victims could discover the same offender is responsible.

The newer and less used Voluntary Donors Index consists of DNA profiles voluntarily submitted by any person, other than a victim, and may be used to advance a criminal, missing persons or human remains investigation. Volunteers are typically people with a missing loved one or a relative suspected in a crime.

As the NDDB was becoming established, it took more than three years to reach the milestone of 1,000 offender hits. Now, the NDDB takes less than three months to achieve each additional 1,000 offender hits.

As more DNA profiles are added to the databank, more matches are made in less time, says the NDDBs latest annual report.

There are more than 401,546 offender profiles in the NDDB.

Offender DNA is collected from those convicted of a wide array of offences that include murder, manslaughter, aggravated sexual assault, sexual assault, child pornography, robbery and assault. An offender profile entered into the NDDB for a less serious offence may assist a much more serious investigation. In 2018-19, offender profiles entered due to assault assisted with 551 murder investigations and 1,250 sexual assaults.

On the trail at a murder scene

At a homicide scene, the collection of DNA evidence is a joint effort between major crime detectives and forensics officers of the Hamilton Police Service.

They all talk about the need for a narrative a basic understanding of what happened before, during and after the death.

Did witnesses see the suspect drink from a bottle of water and toss it aside before the stabbing took place? Did the suspect use a spoon before the shooting?

We like to get a narrative before forensics goes in, so they dont seize 30 water bottles or every spoon in the house, says Staff Sgt. Dave Oleniuk, a former homicide detective. But we also have to keep an open mind. You have to follow the evidence.

When a homicide happens, the call goes out to whichever one of the units three staff sergeants is on deck to be the major case manager. He will then contact the divisional staff sergeant to find out what is happening at the scene which is being controlled by uniformed officers.

The case manager usually has his investigative team meet at the station for a briefing, along with forensics officers, so all the key players hear the same thing, says Oleniuk. That information will have come from the first officers at the scene who are also brought into the briefing and other witnesses.

That information will also be used to obtain a search warrant, guide the forensics unit in collecting evidence and help homicide detectives decide who to interview.

After the briefing, detectives and forensics officers are ready to work the scene.

Its really hard to do a scene if you have no idea whats happened, says Huys. Sometimes its super obvious.

If someone is shot in their driveway, there is no need to do forensics inside the home, she says.

Which was a good thing in the case of mobster Angelo Musitano, the target of a hit outside his Waterdown home. His family did not co-operate with police.

Sometimes, reading a scene isnt obvious and a bit of a story is needed to focus the collection of evidence and know what to seize, what to swab, where to fingerprint, says Huys.

She references The Sandbar, an infamous former downtown crack house. It was the site of two killings and was rife with fluid stains and filth.

Oh my God. Where do we start? Huys wondered when called there for a homicide.

Even if an arrest has been made, the forensics team still processes the scene because evidence gathered will be used to support the arrest in court. Even a murder/suicide gets the full treatment because there is only one chance at a crime scene.

The forensics team may need to bunny suit up in protective white disposable jumpsuits depending on the situation and extensively videotape and photograph the scene, before anything is touched, says Huys. They document any outdoor portion of the scene first, then the most direct path to the body.

Forensics officers adjust to environmental conditions. An outdoor scene must be covered and processed quickly in rain or snow. A body in a hot apartment must be removed as soon as possible.

Officers hone in on bullet casings and visible blood spots. Then they look closer for hair and fibres.

We work in layers, says Huys. We start with the obvious and then deconstruct a scene.

At a shooting, that could mean cutting holes in walls to retrieve bullets. It might involve spraying chemicals to find traces of blood after a cleanup effort.

If the units blood spatter expert, Mark Miller, is required, he takes his own pictures and collects his own swabs.

Huys seizes smaller items to process in her lab at the station because its a controlled environment. Vehicles are towed to a secure area for the same reason.

The deceased is also a crime scene, says Huys. A forensics officer attends the autopsy examination to continue collecting evidence.

It is impractical to expect the forensics team to collect every single thing from a scene and have the CFS process it all. Instead, forensics officers consider what tests are available and which samples will produce the best results. They decide to send the entire bloody shirt or just swabs from it.

We always overdo the number of items we send and CFS pares it down for us, says Huys. Police package each item separately and seal and label it. Items are sent by courier or are delivered by officers.

Exhibits not tested are stored at Central Station in the property branch. Wet items like a bloody shirt are properly dried in a locker.

While the CFS expedites tests for cases with an ongoing public safety concern, the volume of material going through the centre means police typically receive test results within two months.

In 2019, Hamilton police submitted 966 DNA samples to the NDDB. That resulted in 164 crime scene index hits matches to the databank and 199 offender hits.

Never miss the latest news from The Spectator, including up-to-date coronavirus coverage, with our email newsletters.

The CFS automatically checks DNA profiles it generates with the NDDB.

Hamiltons forensic unit

Hamilton police has 12 full-time forensic investigators. They are the only members allowed to process homicide and sexual assault scenes, while lesser trained Scenes of Crimes Officers can collect forensic evidence at break and enters, for example. Each full-time forensic investigator has at least five years on the job, is qualified as a sergeant, has undergone nine weeks of forensics training at the Ontario Police College and is ready to make a seven-year commitment to the unit while continuing to take forensics training courses.

Despite the popularity of forensics crime TV shows, not many cops race to be forensics officers. It takes a lot of training and education, and testifying in court is a tremendous responsibility because that evidence can be critical to the outcome of the case.

The forensics unit is crammed into a space at the 1970s era headquarters that was never intended for that purpose. Chief Eric Girt has said risk of cross-contamination of DNA evidence is very real.

A need for a larger, purpose-built forensics unit is a main reason behind construction of the services new $26-million Investigative Services Division building.

The two-storey, 63,000-square-foot building bound by Rebecca, Mary, Wilson and Catharine streets is expected to be completed this year.

It will have four labs (one for processing crime scenes, one for evidence from the accused, another for the victim and one for other purposes) to avoid contamination. All align with CFS protocols. It will also have three forensic exam bays for vehicles.

The building will bring all of ISD under one roof, a testament to the close working relationship forensics has with detectives.

The coach officer tapped to teach rookie Huys the job back in 1997 doubled as a Scenes of Crime Officer (SOCO), armed with fingerprinting kits and cameras to collect basic evidence from simple crime scenes.

They werent together long before the SOCO got called to a break-in.

I knew immediately that was what I wanted to do, says Huys, who had no science background. It was just amazing we could find fingerprints or other evidence to find out who did it.

DNA collection isnt reserved for violent crimes. It is gathered from break and enters as well. Huys says a surprising number of thieves eat or drink something in the home, potentially leaving behind their genetic profile. Or it might be gleaned from blood left at the point of entry a broken window, for instance.

Huys needed to move up the ranks to become a first-class constable and pass her sergeants exam before she could go into forensics.

You have to learn to be a police officer first, she says. Knowing your way around a crime scene and understanding what to look for is as important as knowing how to get a fingerprint.

By 2001, Huys was a SOCO officer, having undergone two weeks of training at the Ontario Police College.

She then applied to be a forensics officer and in 2003 was accepted the first woman to hold the job in Hamilton.

Minutes into her first forensics shift, she got a call from dispatch telling her she was needed at a murder scene.

Huys thought it was a prank.

I laughed and hung up.

Follow this link:
DNA the genetic crime solver - TheSpec.com

Read More...

Scientists need to track genetic diversity of COVID-19 for effective vaccine: U of M study – CTV News Winnipeg

Wednesday, July 8th, 2020

WINNIPEG -- A new study out of the University of Manitoba has determined that in order for the creation of an effective COVID-19 vaccine, experts must track the genetic diversity of the virus

The work, conducted by researchers at the Rady Faculty of Health Sciences and a virology lab at Universidad de Concepcin in Chile, also found that if scientists dont monitor how the virus is changing in different parts of the world, the testing could produce false negative results. Dr. Carlos Farkas, a postdoctoral researcher in pharmacology and therapeutics for the Max Rady College of Medicine and the Research Institute in Oncology and Hematology, was the studys lead author.

To conduct the study, the research team used datasets to look at whole genome sequencing samples from people infected before March 27 with the virus that causes COVID-19.

According to a news release from the university, this team was the first to combine genomic sequencing data from two worldwide sources in order to detect variants by geographic region. The group found 146 different variants.

Dr. Jody Haigh, co-author and associate professor of pharmacology and therapeutics and a senior scientist at the Research Institute in Oncology and Hematology, said one of the major findings was that samples from Washington had a distinctive footprint of viral sequence changes.

About 39 per cent of Washington State samples had this footprint. Asian and European samples were more diverse in terms of changes in viral sequence, but their footprints were clearly different from those in the U.S. samples, Haigh said in the release.

The researchers noted when labs test for SARS-CoV-2 (the virus that causes COVID-19), they use small pieces of DNA that bind to the viral sequence and amplify viral RNA/DNA.

Farkas said in order for a robust positive test result, the DNA needs to exactly match the viral sequence.

If researchers design these primers to bind to regions of the virus that they dont realize have changed in a particular population, there may be poor amplification and the result can be false negatives, Farkas said.

The study did find some changes in viral sequence in regions of the virus where the DNA was supposed to bind, which could explain why there have been some false negative testing results.

Because SARS-CoV-2 is changing rapidly, researchers should be aware of its current local viral footprints in order to design DNA primers that dont bind to regions of the virus that have changed. Other regions of the virus that dont show these changes should be used for designing primers, Haigh said.

The research team hopes its work will impact COVID-19 testing and vaccine development.

Originally posted here:
Scientists need to track genetic diversity of COVID-19 for effective vaccine: U of M study - CTV News Winnipeg

Read More...

Genetic Variation Of COVID-19 Infects Human Cells More Readily Than The Original Says Researchers – Rojak Daily

Wednesday, July 8th, 2020

By now we all have heard that COVID-19 has some genetic variations.

A new study published in the journal Cell has found that the genetic variation of COVID-19 infects human cells more readily than the original that emerged in China.

According to a report in AFP, researchers from the Los Alamos National Laboratory in New Mexico and Duke University in North Carolina partnered with the University of Sheffield's COVID-19 Genomics UK research group to analyse genome samples published on GISAID, an international resource for sharing genome sequences.

In the research, they found that the current variant, called "D614G," makes a small but potent change in the "spike" protein that protrudes from the surface of the virus, which it uses to invade and infect human cells.

The scientists paper was first posted to the medical preprint site bioRxiv in April, but it was criticised because they failed to prove that the mutation itself was responsible for its domination.

This led to additional research where they found those with the genetic variant had more viral particles in them, but without this changing the severity of their disease.

Meanwhile, laboratory experiments showed that the variant is three to six times more capable of infecting human cells.

Lets hope that there is more research on this matter so we could be more prepared.

View original post here:
Genetic Variation Of COVID-19 Infects Human Cells More Readily Than The Original Says Researchers - Rojak Daily

Read More...

Genetics, profession: Heres the reason why eczema happens – Hindustan Times

Friday, July 3rd, 2020

Genetics, profession: Heres the reason why eczema happens - health - Hindustan Times "; forYoudata += ""; forYoudata += ""; forYoudata += ""; count++; if (i === 7) { return false; } }); forYouApiResponse=forYoudata; $(forutxt).html('Recommended for you'); $(foruContent).html(forYoudata); } } }); } else if(forYouApiResponse!=''){ $(forutxt).html('Recommended for you'); $(foruContent).html(forYouApiResponse); } } function getUserData(){ $.ajax({ url:"https://www.hindustantimes.com/newsletter/get-active-subscription?usertoken="+user_token, type:"GET", dataType:"json", success: function(res){ if(res.length>0) { $("[id^=loggedin]").each(function(){ $(this).hide(); }); } } }); } function postUserData(payLoad, elm){ var msgelm=$(elm).parents(".subscribe-update").nextAll("#thankumsg"); $.ajax({ url:"https://www.hindustantimes.com/newsletter/subscribe", type:"POST", data:payLoad, contentType: "application/json", dataType: "json", success: function(res){ if(res.success===true){ $(msgelm).show(); $("[id^=loggedin]").each(function(){ $(this).css("display","none"); }); $("[id^=loggedout]").each(function(){ $(this).css("display","none"); }); } else if(res.exceptionResponse.alreadySubscribed===true){ $(msgelm).show(); $("[id^=loggedin]").each(function(){ $(this).css("display","none"); }); $("[id^=loggedout]").each(function(){ $(this).css("display","none"); }); $(msgelm).find(".subscribed-successfully:first span.msg").text(res.exceptionResponse.message); } } }); }function captchverification(captchaResponse) {$('#captchaResponse').value = captchaResponse;$("#captcha-div").removeClass("block");$("body").removeAttr("style");var payLoad=JSON.stringify({ "domain": "HT", "emailId": email, "googleCaptcha": captchaResponse, "subscriptionTypes": [ "daily" ] });postUserData(payLoad,activeElm);} function subscribeNewsletter(inputText) { activeElm=inputText; var mailformat = /^w+([.-]?w+)*@w+([.-]?w+)*(.w{2,3})+$/; if(inputText.val().match(mailformat)) { inputText.focus(); email=inputText.val(); $("#captcha-div").addClass("block"); $("body").css("overflow","hidden"); return true; } else { alert("You have entered an invalid email address!"); inputText.focus(); return false; } } //DFP Ads var $dfpRightAd1 = $('.dfp-rightAd1-' + storyUuid); var $dfpRightAd2 = $('.dfp-rightAd2-' + storyUuid); var $dfpRightAd3 = $('.dfp-rightAd3-' + storyUuid); var $dfpRightAd4 = $('.dfp-rightAd4-' + storyUuid); var $dfpRightAd5 = $('.dfp-rightAd5-' + storyUuid); var $dfpStoryAd1 = $('.dfp-storyAd1-' + storyUuid); var $dfpStoryAd2 = $('.dfp-storyAd2-' + storyUuid); var $dfpStoryAd3 = $('.dfp-storyAd3-' + storyUuid); var $dfpStoryAd4 = $('.dfp-storyAd4-' + storyUuid); var $dfpStoryAd5 = $('.dfp-storyAd5-' + storyUuid); var $centerAd = $('.centerAd-' + storyUuid); getPersonlizeData(''); displayAd($dfpRightAd1,'/1055314/HT_StoryPages_300x250_Top',[[300, 250], [300, 600]]); displayAd($dfpRightAd2,'/3106570/HT_Desk_Story_BS_Multisize',['fluid', [300, 100]]); var rightMiddleScrollHandler = function () { if ($dfpRightAd3.isInViewport()) { displayAd($dfpRightAd3, '/1055314/HT_StoryPages_300x250_Middle', [[300, 250], [300, 600]]); $(window).off("scroll", rightMiddleScrollHandler); } } $(window).on("scroll", rightMiddleScrollHandler); var rightTabRepTopScrollHandler = function () { if ($dfpRightAd4.isInViewport()) { displayAd($dfpRightAd4, '/1055314/HT_Desk_Story_TabRep_Top_Multisize', [[300, 250], [300, 600]]); $(window).off("scroll", rightTabRepTopScrollHandler); } } $(window).on("scroll", rightTabRepTopScrollHandler); var rightTabRepBottomScrollHandler = function () { if ($dfpRightAd5.isInViewport()) { displayAd($dfpRightAd5, '/1055314/HT_Desk_Story_TabRep_Bottom_Multisize', [300, 250]); $(window).off("scroll", rightTabRepBottomScrollHandler); } } $(window).on("scroll", rightTabRepBottomScrollHandler); var storyCenterScrollHandler = function () { if ($centerAd.isInViewport()) { displayAd($centerAd, '/1055314/HT_Desk_Story_ES_Top_728x90', [728, 90]); $(window).off("scroll", storyCenterScrollHandler); } } $(window).on("scroll", storyCenterScrollHandler); //Inline story ads var storyAd1ScrollHandler = function () { if ($dfpStoryAd1.isInViewport()) { displayAd($dfpStoryAd1, storyAdList[0].ad, [728, 90]); $(window).off("scroll", storyAd1ScrollHandler); } } $(window).on("scroll", storyAd1ScrollHandler); var storyAd2ScrollHandler = function () { if ($dfpStoryAd2.isInViewport()) { displayAd($dfpStoryAd2, storyAdList[1].ad, [728, 90]); $(window).off("scroll", storyAd2ScrollHandler); } } $(window).on("scroll", storyAd2ScrollHandler); var storyAd3ScrollHandler = function () { if ($dfpStoryAd3.isInViewport()) { displayAd($dfpStoryAd3, storyAdList[2].ad, [728, 90]); $(window).off("scroll", storyAd3ScrollHandler); } } $(window).on("scroll", storyAd3ScrollHandler); var storyAd4ScrollHandler = function () { if ($dfpStoryAd4.isInViewport()) { displayAd($dfpStoryAd4, storyAdList[3].ad, [728, 90]); $(window).off("scroll", storyAd4ScrollHandler); } } $(window).on("scroll", storyAd4ScrollHandler); var storyAd5ScrollHandler = function () { if ($dfpStoryAd5.isInViewport()) { displayAd($dfpStoryAd5, storyAdList[4].ad, [728, 90]); $(window).off("scroll", storyAd5ScrollHandler); } } $(window).on("scroll", storyAd5ScrollHandler); validateUser($("#loggedin"),$("#loggedout")); if(user_token){ $("#loggedin .subscribe-text").html("Subscribe to get our daily newsletter in your inbox"); $("#loginSub").click(function(){ var udata=JSON.stringify({ "domain": "HT", "userToken": user_token, "googleCaptcha": "string", "subscriptionTypes": [ "daily" ] }); postUserData(udata,this); }); }else{ $("#loggedout .subscribe-text").html("Enter your email to get our daily newsletter in your inbox"); $("#subscribeBtn").click(function(){ subscribeNewsletter($(this).prev()); }); } function ScrollMe(uuid) {var id = uuid.replace('story_','').trim(); id = id +"_story";var newid = uuid.trim();$('#ulInfinite').each(function() {var phrase = '';$(this).find('li').each(function(j, lix) {var myid = $(lix).attr('id');if (myid.trim() == newid.trim())$(lix).addClass("active");else$(lix).removeClass("active");});});var element = document.getElementById(id);element.scrollIntoView();element.scrollIntoView({behavior : "auto",block : "start",inline : "nearest"});$('html, body').animate({scrollTop : $("#" + newid).offset().top - 800}, 800, 'swing');}function InfiniteScroll() {var nextURL = listUrl[urlCount];var $container = $('.articles').infiniteScroll({path : function() {return nextURL;},append : '.article',status : '.scroller-status',hideNav : '.pagination',loadOnScroll : false,scrollThreshold : false});$container.infiniteScroll('loadNextPage');$container.on('history.infiniteScroll', function(event, title, path) {var currentID = "article_" + getStoryIdByUrl('https://www.hindustantimes.com/health/genetics-profession-here-s-the-reason-why-eczema-happens/story-MgDjJoPLXpuqeIo85nNRxM.html');var articleID = "article_" + getStoryIdByUrl(path);document.title = title;var temp = path.replace('.html', '').split('-');temp = temp.reverse();var forNid = temp[0].trim();$('#ulInfinite li').removeClass("active");$('#story_' + forNid).addClass("active");var n = gatag.includes(articleID, 0);if(n==false){gatag.push(articleID);showSkippablePopup();ga('send', {hitType : 'pageview',location : window.location.hostname.trim(),title : title.trim(),page : window.location.pathname.trim(),dimension15 : title});}window.snowplow("trackPageView", title);window.snowplow('resetPagePing');if (typeof COMSCORE != 'undefined'&& typeof COMSCORE.beacon !== 'undefined') {COMSCORE.beacon({c1 : "2",c2 : "6035286"});}});$container.on('load.infiniteScroll', function(event, response, path) {urlCount++;});var counter = 1;var uuid;$container.on('append.infiniteScroll', function(event, response, path, items) {uuid= $(items).find('.get-uuid').val();var elmLogin=$(items).find('#loggedin');var elmLogout=$(items).find('#loggedout');getPersonlizeData(items); validateUser(elmLogin,elmLogout); if(user_token){ getUserData(); $(elmLogin).find(".subscribe-text").html("Subscribe to get our daily newsletter in your inbox"); $(items).find("#loginSub").click(function(){ var udata=JSON.stringify({ "domain": "HT", "userToken": user_token, "googleCaptcha": "string", "subscriptionTypes": [ "daily" ] }); postUserData(udata, this); }); }else{ $(elmLogout).find(".subscribe-text").html("Enter your email to get our daily newsletter in your inbox"); $(items).find("#subscribeBtn").click(function(){ subscribeNewsletter($(this).prev()); }); }var $dfpRightAd1ES = $(items).find('.dfp-rightAd1-'+uuid); var $dfpRightAd3ES = $(items).find('.dfp-rightAd3-'+uuid); var $dfpRightAd4ES = $(items).find('.dfp-rightAd4-'+uuid); var $dfpRightAd5ES = $(items).find('.dfp-rightAd5-'+uuid); var $centerAdES = $(items).find('.centerAd-' + uuid); var $dfpStoryAd1ES = $('.dfp-storyAd1-' + uuid);var $dfpStoryAd2ES = $('.dfp-storyAd2-' + uuid); var $dfpStoryAd3ES = $('.dfp-storyAd3-' + uuid); var $dfpStoryAd4ES = $('.dfp-storyAd4-' + uuid); var $dfpStoryAd5ES = $('.dfp-storyAd5-' + uuid); var isVideoExists = $(items).find('.video-js'); var isVideo=false; if (isVideoExists.length > 0) { isVideo=true; } var rightESTopScrollHandler = function () { if ($dfpRightAd1ES.isInViewport()) { displayAd($dfpRightAd1ES, rightAdList[0].ad, rightAdList[0].adsizes); $(window).off("scroll", rightESTopScrollHandler); } } $(window).on("scroll", rightESTopScrollHandler); var rightESMiddleScrollHandler = function () { if ($dfpRightAd3ES.isInViewport()) { displayAd($dfpRightAd3ES, rightAdList[1].ad, rightAdList[1].adsizes); $(window).off("scroll", rightESMiddleScrollHandler); } } $(window).on("scroll", rightESMiddleScrollHandler); var rightESTabRepTopScrollHandler = function () { if ($dfpRightAd4ES.isInViewport()) { displayAd($dfpRightAd4ES, rightAdList[2].ad, rightAdList[2].adsizes); $(window).off("scroll", rightESTabRepTopScrollHandler); } } $(window).on("scroll", rightESTabRepTopScrollHandler); var rightESTabRepBottomScrollHandler = function () { if ($dfpRightAd5ES.isInViewport()) { displayAd($dfpRightAd5ES, rightAdList[3].ad, rightAdList[3].adsizes); $(window).off("scroll", rightESTabRepBottomScrollHandler); } } $(window).on("scroll", rightESTabRepBottomScrollHandler); var storyCenterScrollHandler = function () { if ($centerAdES.isInViewport()) { displayAd($centerAdES, '/1055314/HT_Desk_Story_ES_Top_728x90', [728, 90]); $(window).off("scroll", storyCenterScrollHandler); } } $(window).on("scroll", storyCenterScrollHandler); //Story Inline ads var storyESAd1ScrollHandler = function () { if ($dfpStoryAd1ES.isInViewport()) { displayAd($dfpStoryAd1ES, storyAdList[0].ad2, [728, 90]); $(window).off("scroll", storyESAd1ScrollHandler); } } $(window).on("scroll", storyESAd1ScrollHandler); var storyESAd2ScrollHandler = function () { if ($dfpStoryAd2ES.isInViewport()) { displayAd($dfpStoryAd2ES, storyAdList[1].ad2, [728, 90]); $(window).off("scroll", storyESAd2ScrollHandler); } } $(window).on("scroll", storyESAd2ScrollHandler); var storyESAd3ScrollHandler = function () { if ($dfpStoryAd3ES.isInViewport()) { displayAd($dfpStoryAd3ES, storyAdList[2].ad2, [728, 90]); $(window).off("scroll", storyESAd3ScrollHandler); } } $(window).on("scroll", storyESAd3ScrollHandler); var storyESAd4ScrollHandler = function () { if ($dfpStoryAd4ES.isInViewport()) { displayAd($dfpStoryAd4ES, storyAdList[3].ad, [728, 90]); $(window).off("scroll", storyESAd4ScrollHandler); } } $(window).on("scroll", storyESAd4ScrollHandler); var storyESAd5ScrollHandler = function () { if ($dfpStoryAd5ES.isInViewport()) { displayAd($dfpStoryAd5ES, storyAdList[4].ad, [728, 90]); $(window).off("scroll", storyESAd5ScrollHandler); } } $(window).on("scroll", storyESAd5ScrollHandler); counter++;if (urlCount = n && o = n ? t.play() : t.pause()) : console.log("iOS") }) }); }}else if(isVideo){$(items).find("video[id^='myPlayerID_']").each(function(t, e) {var n = "myPlayerID_" + $(e).attr("data-video-id");bc(n), videojs(n).ready(function() {this.scrollIntoView()}) });}$(items).find("div[id^='right-swiper-']").each(function(i, e) {var swipID = $(e).attr("id");var storySwiper = new Swiper('#' + swipID, {pagination : {el : '.swiper-pagination',clickable : true},preloadImages : false,lazyLoading : true,simulateTouch : false,autoplay : {delay : 3000,}});});var ind = 0;$(items).find('.read-more').each(function(ind, obj) {ind = ind + 1;var html = $(items).find("#inlineStory" + ind).html();$(this).html(html);});$(items).find('img.lazy').each(function(i, e) {$(e).lazyload({effect : "fadeIn",effectTime : 20,threshold : 200,failurelimit : 0});});//getSeoContent(items);});}var reqOpen = true;$(document).bind("scroll",function() {var viewport = {top : $(document).scrollTop(),left : $(document).scrollLeft()};viewport.bottom = viewport.top + $(document).height();lastScrollTop = viewport.top;var bot = viewport.bottom - $(document).height();if (viewport.top > 200 && (showInfinite)) {if(isCorona && !loaded){var s= document.createElement('script');s.setAttribute('async','');s.src="https://chat.amplify.ai/plugin/5e77327dd8722a5cf17170be/chat_plugin.js?pluginId=5e77327dd8722a5cf17170be";document.getElementsByTagName('head')[0].appendChild(s);loaded=true;}$('.footer-scroll-main').show();if (reqOpen == true) {$('#ulInfinite li:first').addClass("active");$('#ulInfinite li .stroy-link').each(function(i, t) {if(i>0){listUrl.push($(t).html());}});InfiniteScroll();reqOpen = false;} } else if (bot

More here:
Genetics, profession: Heres the reason why eczema happens - Hindustan Times

Read More...

Wound Healing | Slow Wound Healing? It Could Be Your Genetics – runnersworld.com

Friday, July 3rd, 2020

Maybe you take a spill on an asphalt path and scrape your knees, and on that same day, a fellow runner friend does the same on a trail run. Days later, your friend only has minor evidence of the incident, while your scrapes still look fresh. Is it the difference between dirt and pavement?

The more likely answer is that the difference could be related to genetics, according to new research.

The study, published in PLOS Pathogens, found that genetic variability across 164 patients influences the composition of wounds and how they heal. Specifically, the forms of bacteria present in wounds have a genetic component that could make it easier to identify who would struggle with slower wound healing.

Researchers found that genetic variation in two genes, TLN2 and ZNF521, was associated with both the number of bacteria in wounds and the prevalence of common pathogens that causes slower healing.

Its important to note that the study was done on chronic wounds, which dont heal under a normal timeframe, according to lead study author Caleb Phillips, Ph.D., assistant professor of biological sciences and curator of genetic resources at Texas Tech University.

About two percent of Americans are afflicted with these kind of wounds, and they can be costly and frustrating to treat. Finding a genetic link like this could be a first step toward creating prevention strategies or developing new treatments, he told Runners World. It could also be used to identify patients who need to receive more aggressive therapy early on in wound care, rather than waiting weeks for the bodys healing process to kick in.

[Run faster, stronger, and longer with this 360-degree training program.]

You cant swap out your genes to help speed up the healing of your wounds. But there actually are some tactics that may cut down on healing time, previous research has found.

For example, get more sleep. A 2018 study in Journal of Applied Physiology that measured immune response and skin barrier restoration on people with minor blisters found that those who had restricted sleep showed slower wound healing than those who got adequate shuteye.

Good nutrition also plays a part, and research done on older people with chronic wound issues, which was published in Advanced Wound Care, found that common micronutrient deficienciesparticularly vitamin D, zinc, and B12could have a significant impact on wound healing.

Lifestyle changes like those mentioned above might not counteract genetic differences completely, but they may speed up healing to some degree, and also provide all the other benefits of quality sleep and good nutrition.

This content is created and maintained by a third party, and imported onto this page to help users provide their email addresses. You may be able to find more information about this and similar content at piano.io

This commenting section is created and maintained by a third party, and imported onto this page. You may be able to find more information on their web site.

See the original post:
Wound Healing | Slow Wound Healing? It Could Be Your Genetics - runnersworld.com

Read More...

Why Seattle Genetics Shares Climbed 48.7% in the First Half – Motley Fool

Friday, July 3rd, 2020

What happened

Seattle Genetics (NASDAQ:SGEN) shares rose 48.7% in the first half, according to data provided by S&P Global Market Intelligence, after the company gained U.S. regulatory approval for its second drug in less than six months.

Image source: Getty Images.

The U.S. Food and Drug Administration in April approved Tukysa for patients with metastatic HER2-positive breast cancer after approving Padcev in December for locally advanced or metastatic urothelial cancer. In Padcev's first full quarter of commercialization, the drug generated $34.5 million in net sales, the company reported.

Urothelial cancer is the most common form of bladder cancer, and according to Grand View Research, the global drug market for the disease is growing at a 22.9% compound annual growth rate and is set to reach $3.6 billion by 2023. The global HER2-positive breast cancer market, at a 4.4% compound annual growth rate, may reach nearly $10 billion by 2025, a Global Data report shows. With these growing markets, Tukysa and Padcev have plenty of room to deliver sales increases.

Seattle Genetics' drug Adcetris, for Hodgkin lymphoma, was approved in 2011. Adcetris sales climbed 22% in the first quarter, and the company forecasts more growth as it works to further establish the drug as part of a frontline treatment, or first treatment given to patients.

The European Medicines Agency is currently reviewing Tukysa, so investors will be watching for a possible approval in Europe. Sales figures from Padcev's second quarter on the market will be another factor that could offer the stock direction in the second half of the year.

In more positive news, Seattle Genetics recently reported encouraging data from its phase 2 trial of tisotumab vedotin for recurrent or metastatic cervical cancer. The biotech company plans to speak with the FDA about the possibility of an accelerated approval process for the drug candidate. If the FDA agrees to an accelerated pathway, that likely will be another positive driver for Seattle Genetics' shares.

Read more from the original source:
Why Seattle Genetics Shares Climbed 48.7% in the First Half - Motley Fool

Read More...

With unprecedented amounts of genetic data, researchers are tracking how COVID-19 mutates around the world – ZDNet

Friday, July 3rd, 2020

A view of the phylogeny of the N protein of the SARS-CoV-2 coronavirus, one of the key parts of the virus, seen as diverging versions, or sequences, that are spread throughout the world. Dumonteil and Herrera use smart software that can make statistical inferences about how one sequence relates to another and therefore how sequences are evolving from the original form of the virus.

The world has been obsessed with surveillance of a particular kind for six months: watching people to see who's sick.

There is another form of surveillance that is just as important but less well understood, and that is the attempt to track how the SARS-CoV-2 virus itself is changing as it spreads around the world.

COVID-19 , like other coronaviruses, evolves rapidly. The particular order of nucleic acids encoded in its RNA, the genetic instructions that create the proteins that make up the virus, change over time. (Humans have a double-stranded DNA, whereas viruses, for evolutionary reasons, have the single-stranded genetic material RNA.)

That rapid change in RNA is a problem for efforts to counter the virus that depend on knowing what the virus looks like at a molecular level. The many vaccines in development, for example, will only work if they're tuned to the proper sequence of amino acids that are in the virus in its current form. If the virus that's circulating among people suddenly morphs a different sequence, it could render a vaccine useless.

The same is true for serologic tests that measure the presence of antibodies in people who've had the disease. They work by testing blood by presenting a small bit of the virus's genetic information, known as the antigen, to see if anything in the blood responds to that antigen. If a response is seen, that means there are antibodies. Hence, such tests won't work if the antigen, the piece of virus protein, changes form.

So scientists are trying to develop an ongoing family tree that records how the virus changes form.

Scientists Eric Dumonteil and Claudia Herrera of the School of Public Health and Tropical Medicine at Tulane University this month described their attempts to build such a family tree using 18,247 samples of the viral RNA, what they refer to as "a global analysis of viral diversity across the world."

Their paper, "Polymorphism and selection pressure of SARS-CoV-2 vaccine and diagnostic antigens: implications for immune evasion and serologic diagnostic performance," was posted June 18th on the bioRxiv pre-print server. The work has not been reviewed yet by peer researchers, and so its findings have to be taken with great caution.

The samples of COVID-19 RNA can be downloaded as files from GISAID, a database hosted by Germany that is drawn upon by scientists all over the world. The U.S. Centers for Disease Control has been a technical partner supporting the database since its creation in 2006.

To see how those thousands of samples relate to one another, Dumonteil and Herrera turned to a software package called FastTree, developed by Morgan N. Price and colleagues at Lawrence Berkeley National Laboratory in 2009.

FastTree is designed to infer phylogenies, which means to calculate how close one sample of DNA or RNA is to another to the extent that it could have evolved from it by some change of one or more nucleic acids. To do that with thousands of samples of genetic material is a large combinatorial problem that can quickly get out of hand in terms of computing power required. Just the storage in computer memory needed to hold the values of all those examples quickly rises into the tens of gigabytes.

So FastTree takes some shortcuts, such as grouping together samples of RNA as profiles that summarize how any two differ from one another. It's a kind of data compression, if you will, that makes it easier to search and compare the large collections of RNA.

Once the phylogenies, or family trees, are constructed with FastTree, a second program, HyPhy, is used to test out various hypotheses about how one sample of RNA may have evolved from another. The software was first introduced in 2000 by statistician Spencer Muse of North Carolina State University and biologist Sergei Kosakofsky Pond of Temple University.

The conclusion that Dumonteil and Herrera arrive at is that COVID-19 is "a fast evolving virus, as it is rapidly accumulating mutations." And it's not just changes in a particular area of RNA, it's widespread. The changes in nucleic acids are "scattered through the viral genome, rather than clustered in specific genes," the authors write. Several new "clades" have been emerging, where a clade is a cluster of examples that share a common parent from which they sprung. It's like a new colony of settlers setting up in a new land.

The scientists are seeing evolutionary pressure at work as the virus seeks to evade the body's immune system. Like every organism, natural selection means that as mutations happen in the virus, some will come to dominate because they help it better survive in any number of ways, whether it's attaching to the human cell better or replicating better.

ZDNet reached out to Dumonteil in email to ask follow-up questions.

Even by the standards of rapidly evolving coronaviruses, the number of mutations seemed substantial, Dumonteil indicated to ZDNet.

"The size of the pandemic has also allowed for a considerable number of virus generations within a relatively short time, so these changes may also reflect virus ongoing adaptation to a new host (humans)," Dumonteil told ZDNet by email.

"The selection pressure we detected is part of this process and it does reflect how our immune system is attempting to control the virus," he said.

What's less clear at this point is whether the number of rapid mutations means humans are presenting a formidable challenge or if, on the contrary, the virus is doing so well that it has more opportunity to evolve. It's hard to make definitive conclusions because the scale of the data introduces statistical uncertainty. The rapidity of mutation could simply be a result of the abundance of viral samples gathered.

"The percentage of variability in these antigens from SARS-COV-2 seems high compared to other RNA viruses, but this may be due to the unprecedented level of sequence data available," Dumonteil told ZDNet.

Dumonteil said it's not clear yet from the lineages themselves how successful humans have been at fighting the virus. To draw any conclusion would be going beyond what the data show.

For the time being, the key parts of the virus that a serologic test or a vaccine would aim for are well conserved, meaning, they're not changing as much as they might. For example, what's called the S protein, part of which attaches to proteins on the surface of a human cell to gain entry to the cell and replicate the virus, is "highly conserved." For that reason, vaccines or tests looking for the distinct form of the S protein should work.

But ongoing surveillance will be necessary because Dumonteil and Herrera can already see changes in the S protein that are making it diverge from what was seen with the earliest samples of the virus from China. "Most of these variants appeared in the past weeks/months and may be slowly replacing the virus presenting sequences similar to that of the initial isolates from Wuhan, China," they write in the report.

It's a matter of keeping on top of things, Dumonteil told ZDNet. "We are certainly interested in following these changes over time as new sequences become available, as this will allow to adjust both diagnostic tests and vaccine candidates."

Oliver Pybus and colleagues at The University of Oxford used the phylogenies to track by what geographic routes the virus came into the U.K., a kind of genetic passport.

Such analysis is going on all over the world, and it turns up different findings in the hands of different researchers.

For example, Oliver Pybus and colleagues at Oxford this month described how the virus changed form in samples observed in the United Kingdom alone. They used the phylogenies to track where the virus came from geographically like a kind of genetic passport.

By constructing phylogenetic trees, they could infer how much of COVID-19 in the U.K. came from foreign travelers who entered the country in March before global travel bans went into effect. A third of the COVID-19 infection cases may have been imported from Spain, they estimate, another third from France, and the balance from Italy and other countries.

Again, a lot of caution has to be exercised because such knowledge is constructed from statistical tools and is only an approximation of what may have transpired. Nevertheless, Dumonteil's use of the word "unprecedented" to characterize the scale of these projects is worth lingering on. The kinds of viral surveillance going on may yield a scientific picture of infection around the world that is unlike any picture of disease humanity has ever constructed before.

Read the rest here:
With unprecedented amounts of genetic data, researchers are tracking how COVID-19 mutates around the world - ZDNet

Read More...

Genotype analysis of six popular dog breeds finds reduced genetic diversity within subpopulations – Omak Okanogan County Chronicle

Friday, July 3rd, 2020

VANCOUVER, Wash., June 30, 2020 /PRNewswire/ --Wisdom Health Genetics, the world's leader in pet genetics and makers of the WISDOM PANELdog DNA tests, announced today the publication in Canine Medicine and Genetics of a study conducted in collaboration with the University of Eastern Finland.

The study, Variation in breeding practices and geographic isolation drive subpopulation differentiation, contributing to the loss of genetic diversity within dog breed lineages,describes genetic subpopulation differentiation and related loss of genetic diversity discovered in six dog breeds: the Belgian Shepherd, English Greyhound, Finnish Lapphund, Italian Greyhound, Labrador Retriever, and Shetland Sheepdog.

Researchers examined the six popular dog breeds based on differential breeding strategies -- such as breeding for characteristics desired in 'sporting' compared to 'show' lines -- and geography using genotype analysis, finding that each of the breeds showed subpopulation differentiation contributing to a lack of genetic diversity.

For the Italian Greyhound and Shetland Sheepdog, the differentiation could be attributed to the founder effect -- or the reduction in genetic diversity caused when a population descends from a small number of 'founding' ancestors, combined withgeographical isolation based on continent. Breeder preferences accounted for the genetic structure of the remaining four breeds: the English Greyhound and Labrador Retriever breed structures were selected for either show, sport, or working lineages. Analysis of the Belgian Shepherd breed structure shed light on the genetic relationships between different subvarieties of the breed; analysis of the Finnish Lapphund revealed a relatively recent, unexpected split within that subpopulation due to breeder preference.

"These findings are yet another example of how the genetic data generated during our commercial testing at Wisdom Health Genetics can be used to gain insight into the population structure and diversity levels of breeds and their subpopulations," said Jonas Donner, PhD, Discovery Manager at Wisdom Health Genetics.

Though breed differentiation can serve important purposes, selection must be done critically and carefully to maintain healthy genetic diversity and increase gene flow between isolated populations.

"Breeding dogs to fulfill specific breed ideals, by definition, will result in a loss of variation over time; this differentiation is not generally negative. However, due to their size, many small breed populations are in danger of suffering from the accumulated effects of inbreeding depression over the generations," said study co-author Jaakko Pohjoismaki, PhD, senior researcher in genetics at the University of Eastern Finland. "Breed organizations should be more proactive in mixing the dogs between specialized lineages or closely related breeds to prevent deleterious effects of inbreeding depression."

It is essential to maintain a balance between preserving diversity within the breeds when selecting for desired characteristics; to continue responsible breeding, genetic diversity and selecting for positive health traits are central to keeping a population healthy.

"The results of this study highlight the importance of careful balancing between selection for desired traits and health, and avoiding loss of genetic diversity," said Rebecca Chodroff Foran, PhD, R&D Director at Wisdom Health Genetics. "Through our research, we aim to improve the lives of pets everywhere, and identifying opportunities to maintain genetic diversity will ultimately help create and support healthier populations."

Based on the observed loss of genetic diversity in subpopulations of the six breeds studied, the researchers recommend that breeders take steps to encourage genetic diversity, facilitating exchange of dogs across geographical borders and avoiding unnecessary artificial boundaries between lineages.

About the Subpopulation Genetic Differentiation Study:

About Wisdom Health Genetics

The mission of the Wisdom Health business is to strengthen the bond between pets and their people through world-leading insights powered by DNA. Wisdom Panel dog DNA tests - backed by the WISDOM HEALTH scientific research - can help pet parents plan better, care smarter, and love longer. For more than a decade, Wisdom Health scientific research contributed to develop state-of-the-art genetic tests for companion animals, revolutionizing personalized pet care. By unlocking the secrets of their dog or cat's DNA, pet parents and veterinarians can work together to tailor wellness programs that fit the one-of-a-kind needs of their pets. Wisdom Panel products are recommended by veterinarians, and the tests are currently offered by 7000+ veterinarians worldwide. For more information, visithttp://www.wisdompanel.com, or follow the Wisdom Panel brand onFacebook andInstagram.

About Kinship Labs

Advances in science, technology, health and nutrition offer an opportunity to transform the $100B+ pet care industry. With industry-leading data and analytics capabilities, a $100M venture fund and pioneering startup accelerator program, unique set of technology businesses like Whistle Labs and Wisdom Health Genetics,Kinship Labs is building the first-of-its-kind coalition of partners to transform the future of pet care. Kinship Labs is a business division of Mars Petcare, the global leader in pet health, nutrition and services, dedicated to one purpose:A BETTER WORLD FOR PETS. Follow @kinshipco to learn more.

About Mars Petcare

Part of Mars, Incorporated, a family-owned business with more than a century of history making diverse products and offering services for people and the pets people love, the 85,000 Associates across 50+ countries in Mars Petcare are dedicated to one purpose: A BETTER WORLD FOR PETS. With 85 years of experience, our portfolio of almost 50 brands serves the health and nutrition needs of the world's pets including brands PEDIGREE, WHISKAS, ROYAL CANIN,NUTRO, GREENIES, SHEBA, CESAR, IAMS and EUKANUBA as well as the Waltham Petcare Science Institute which has advanced research in the nutrition and health of pets for over 50 years. Mars Petcare is also a leading veterinary health provider through an international network of over 2,000 pet hospitals and diagnostic services including BANFIELD, BLUEPEARL, VCA, Linnaeus, AniCura and Antech. We're also active in innovation and technology for pets, with Wisdom Panel genetic health screening and DNA testing for dogs, the WHISTLE GPS dog tracker, LEAPVENTURE STUDIOaccelerator and COMPANION FUND programs that drive innovation and disruption in the pet care industry. As a family business guided by our principles, we are privileged with the flexibility to fight for what we believe in and we choose to fight for our purpose: A BETTER WORLD FOR PETS.

Media Contact:Lesley Albertlesley.albert@effem.com

Continue reading here:
Genotype analysis of six popular dog breeds finds reduced genetic diversity within subpopulations - Omak Okanogan County Chronicle

Read More...

Global Animal Genetics Market 2020 Report with Segmentation, Analysis on Trends, Growth, Opportunities and Forecast Till 2025 – Jewish Life News

Friday, July 3rd, 2020

Global Animal Genetics Market 2020-2025 report draws precise insights by examining the latest and prospective industry trends and helping readers recognize the products and services that are boosting revenue growth and profitability. The Animal Genetics market study performs a detailed analysis of all the significant factors, including drivers, constraints, threats, challenges, prospects and industry-specific trends, impacting the market on a global and regional scale. Additionally, the report worldwide market scenario along with competitive landscape of leading participants.

Get sample copy of Animal Genetics Market report @ https://www.adroitmarketresearch.com/contacts/request-sample/603

Global Animal Genetics Market research study comprises 100+ market data Tables, Graphs & Figures, Pie Chat to understand detailed analysis of the market. The predictions estimated in the market report have been resulted in using proven research techniques, methodologies, and assumptions. This Global Animal Genetics Market report states the market overview, historical data along with size, growth, share, demand, and revenue of the global industry. It incorporates market evolution study, involving the current scenario, growth rate, and capacity inflation prospects, based on Porters Five Forces and DROT analyses.

Top Leading Key Players are:

Envigo, Groupe Grimaud, Alta Genetics, NEOGEN CORPORATION and Hendrix Genetics.

Read complete report with TOC at: https://www.adroitmarketresearch.com/industry-reports/animal-genetics-market

The research report of the global Animal Genetics market offers broad analysis about the industry on the basis of different key segments. Moreover, the research report presents a comprehensive analysis about the opportunities, new products, and technological innovations in the market for the players. The research report on the global Animal Genetics market helps clients to understand the structure of the market by identifying its various segments such as product type, end user, competitive landscape and key regions. Reports provide the description about the profile of the top manufacturers of the global Animal Genetics market.

Global Animal Genetics market is segmented based by type, application and region.

Based on Type, the market has been segmented into:

By Procedure, (Genetic disease tests,Genetic trait tests,DNA typing), By Animal Type, (Equine,Canine,Bovine,Porcine,Poultry,Others)

Geographically, this Animal Genetics market report split global into several key Regions, revenue (Million USD) the geography (North America, Europe, Asia-Pacific, Latin America and Middle East & Africa) focusing on key countries in each region. It also covers market drivers, restraints, opportunities, challenges, and key issues in Global Animal Genetics Market. The report offers regional expansion of the industry with their product analysis, market share, and brand specifications.

Global Animal Genetics Market research report, besides ample understanding shared in the previous sections, the report also presents this comprehensive research report gauges for decisive conclusions concerning growth factors and determinants, eventually influencing holistic growth and lucrative business models in Global Animal Genetics Market. The report on this target market is a judicious compilation of in-depth and professional marketing cues that are crucially vital in delegating profit driven business decisions.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry Expert @ https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/603

About Us :

Adroit Market Research is an India-based business analytics and consulting company. Our target audience is a wide range of corporations, manufacturing companies, product/technology development institutions and industry associations that require understanding of a markets size, key trends, participants and future outlook of an industry. We intend to become our clients knowledge partner and provide them with valuable market insights to help create opportunities that increase their revenues. We follow a code Explore, Learn and Transform. At our core, we are curious people who love to identify and understand industry patterns, create an insightful study around our findings and churn out money-making roadmaps.

Contact Us :

Ryan JohnsonAccount Manager Global3131 McKinney Ave Ste 600, Dallas,TX 75204, U.S.APhone No.: USA: +1 972-362 -8199 / +91 9665341414

See the article here:
Global Animal Genetics Market 2020 Report with Segmentation, Analysis on Trends, Growth, Opportunities and Forecast Till 2025 - Jewish Life News

Read More...

Hemp Genetics CEO on Selecting the Right Strains – Greenhouse Grower

Friday, June 26th, 2020

The sheer volume of genetics in the hemp and legal cannabis markets introduces a bit of uncertainty into perhaps the most important decision a commercial cannabis grower will make all year. Its definitely not as easy a choice as Coke vs. Pepsi(#TeamCoke!)

Whether youre growing hemp for pure biomass yield, greenhouse cannabis flower for the top shelf down at the local dispensary, or producing exclusively for the extraction market, making the right decision with your seed or clone salesperson can often make or break a farmers crop.

As part of last weeks Experience Hemp: Summer Solstice Virtual Conference and Trade Show, Beacon Hemp CEO Nick Stromberg gave a brief presentation laying out the factors hemp growers should keep in mind when selecting their genetic material at the start of the grow season.

I cant stress enough how very important it is to keep the end use of the plant in mind at all times when selecting the best hemp genetics for your farm and for the product youre creating, Stromberg explained to the virtual audience. Am I growing for oil extraction, or fiber and biomass? Will I field dry it, or mechanical dry it? Am I trying for high end CBD or CBG production? Those are just a few of the sort of things you need to have in mind.

How your plants get their start in life is another factor to weigh heavily when selecting strains, according to Stromberg.

Thats another consideration: How are you propagating your starts? And if you dont have a lot of hands on experience in this area, then we highly recommend working with a professional propagator, he said. Uniform, well-hardened seedlings are very key to securing success in this market.

Hemp and cannabis growers have bemoaned a general lack of professionalism among breeders in the segment for years now, with the criticism only growing louder as more states legalize cannabis and hemp production and more growers get burned by bad actors in the seed game. It happens more often that youd think, and Stromberg had some thoughts on how to best evaluate a potential genetics partner.

The Certificate of Analysis (CoA) is going to be one of the biggest selling points that any seed salesman or broker will use to try to sell you, he said. On that document, you want to look closely at both the CBD to THC ratio, or the proportion of CBD to THC in that strain this should be more or less in the mid 20:1 into the low 30:1, and then whether the data youre looking at is from a pre-harvest or a post-harvest CoA.

Those THC/CBD levels should remain fixed throughout the crops development, regardless of growing stage, Stromberg advised. The pre-harvest CoA is your official CoA, and the post-harvest CoA will often go over the .03% THC cap and typically be in the mid to high teens on CBD content, depending how long the pre-harvest interval lasted.

The seed packaging itself should have a certain level of disclosed information about the strain or cultivar contained within as well, Stromberg advised. While Association of Seed Certifying Agency (AOSCA) certified hemp varieties are currently few and far between (AOSCA certification wont come to legal cannabis genetics until federal legalization is passed) with the certification process still in its early stages, a seed tag, or label, should conceivably track somewhat closely (generally speaking) to what corn and soy farmers see when they pick up a bag of RoundupReady2Xtend corn. (SPOILER ALERT: Right now, they dont. A standardization of the reporting process on cannabis and hemp seed labels would be a great thing for growers in this industry, but thats perhaps a subject for another day)

Federal Seed Act compliant labels will list things like germination rate and purity test results those two specifically are legally required to be listed on the seed label as well things like seed lot numbers, dates of testing, all those types of things, he said.Stromberg perhaps saved his best advice for growers for last.

Ask for any additional information on the genetics and its pedigree ask about their background as a plant breeder, the length of the breeding project, their production methods was it produced in the field, or in a greenhouse? And when was it produced ask these questions and youll probably be able to find the legitimate ones are willing to reveal this type of information where others maybe wont.

And ask for regionally significant trial data, he added. If you grow in North Carolina and all the field data is from Oregon, thats probably not what you want to see. The good news is theres been a lot more field trials planted this year. So, going into 2021, there should be a lot more field trial data for those breeders and seed salesmen to hang their hats on.

Want to learn more about commercial hemp varieties? Stay tuned in August for our first-ever commercial hemp varieties guide (alongside our annual coverage of ornamental and greenhouse vegetable varieties).

Matthew J. Grassi is the Technology Editor for Greenhouse Grower and American Vegetable Grower, both Meister Media Worldwide brands. See all author stories here.

See the original post:
Hemp Genetics CEO on Selecting the Right Strains - Greenhouse Grower

Read More...

Page 15«..10..14151617..2030..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick